Table 2 Residual activity and corresponding reduction factors of envelope-pseudotyped lentiviral vectors based on trypsin treatment.

From: The stability of envelope-pseudotyped lentiviral vectors

Envelope protein

Residual activity (±SD)a (%)

Reduction factorb

VSV-G

104

±15

1

Measles

23

±3

4

GALV

1

±1

79

Rabies

61

±11

2

RD114

1

±0.2

110

4070A

26

±15

4

MULV

10

±1

10

  1. aThe average percentage of residual envelope-pseudotyped lentiviral vector activity after trypsin treatment is calculated by dividing the % of GFP-positive cells transduced by trypsin-treated envelope-pseudotyped lentiviral vectors by the % of GFP-positive cells transduced by mock-treated vectors, ±standard deviation. n = 2 independent experiments with technical duplicates, for Measles, RD114 or MULV pseudotyped vectors, n = 3 independent experiments with technical duplicates (The 10A1-pseudotyped vector lost all GFP activity upon purification and was not included in these analyses.).
  2. bThe reduction factor based on the inactivation of the pseudotyped lentiviral vectors by trypsin is calculated by 100 divided by the percentage of residual activity after trypsin treatment.
Back to article page